NorthCoast Asset Management LLC Has $1.41 Million Holdings in Eli Lilly and Company (LLY)
NorthCoast Asset Management LLC decreased its stake in Eli Lilly and Company (NYSE:LLY) by 49.8% in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 17,180 shares of the company’s stock after selling 17,042 shares during the quarter. NorthCoast Asset Management LLC’s holdings in Eli Lilly and were worth $1,414,000 as of its most recent SEC filing.
A number of other institutional investors and hedge funds also recently modified their holdings of the business. Financial Counselors Inc. increased its position in Eli Lilly and by 0.4% in the second quarter. Financial Counselors Inc. now owns 92,508 shares of the company’s stock worth $7,613,000 after buying an additional 350 shares in the last quarter. Martingale Asset Management L P increased its position in Eli Lilly and by 143.3% in the second quarter. Martingale Asset Management L P now owns 333,046 shares of the company’s stock worth $27,411,000 after buying an additional 196,167 shares in the last quarter. Alliancebernstein L.P. increased its position in Eli Lilly and by 2.3% in the second quarter. Alliancebernstein L.P. now owns 3,556,920 shares of the company’s stock worth $292,735,000 after buying an additional 79,549 shares in the last quarter. Aberdeen Asset Management PLC UK increased its position in Eli Lilly and by 13.8% in the second quarter. Aberdeen Asset Management PLC UK now owns 268,608 shares of the company’s stock worth $22,106,000 after buying an additional 32,576 shares in the last quarter. Finally, HPM Partners LLC increased its position in Eli Lilly and by 106.3% in the second quarter. HPM Partners LLC now owns 12,822 shares of the company’s stock worth $335,000 after buying an additional 6,607 shares in the last quarter. Institutional investors and hedge funds own 75.66% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: “NorthCoast Asset Management LLC Has $1.41 Million Holdings in Eli Lilly and Company (LLY)” was originally published by Watch List News and is owned by of Watch List News. If you are reading this article on another site, it was copied illegally and republished in violation of US and international copyright & trademark laws. The correct version of this article can be read at https://www.watchlistnews.com/northcoast-asset-management-llc-has-1-41-million-holdings-in-eli-lilly-and-company-lly/1677345.html.
A number of brokerages have commented on LLY. BMO Capital Markets set a $73.00 price target on Eli Lilly and and gave the stock a “sell” rating in a research report on Wednesday. Zacks Investment Research cut Eli Lilly and from a “buy” rating to a “hold” rating in a research report on Monday, October 30th. Berenberg Bank restated a “buy” rating and issued a $98.00 price target on shares of Eli Lilly and in a research report on Thursday, October 26th. Leerink Swann upped their price target on Eli Lilly and from $92.00 to $93.00 and gave the stock a “market perform” rating in a research report on Monday, October 23rd. Finally, Piper Jaffray Companies restated a “buy” rating and issued a $105.00 price target on shares of Eli Lilly and in a research report on Friday, October 13th. Three research analysts have rated the stock with a sell rating, eight have issued a hold rating and ten have assigned a buy rating to the company. Eli Lilly and currently has a consensus rating of “Hold” and an average price target of $89.76.
Eli Lilly and Company (LLY) opened at $83.51 on Friday. The company has a quick ratio of 1.01, a current ratio of 1.38 and a debt-to-equity ratio of 0.66. The company has a market cap of $91.53 billion, a P/E ratio of 20.33, a P/E/G ratio of 1.83 and a beta of 0.34.
Eli Lilly and (NYSE:LLY) last announced its quarterly earnings results on Tuesday, October 24th. The company reported $1.05 EPS for the quarter, beating analysts’ consensus estimates of $1.03 by $0.02. Eli Lilly and had a return on equity of 30.27% and a net margin of 9.90%. The company had revenue of $5.66 billion during the quarter, compared to analyst estimates of $5.52 billion. During the same period in the prior year, the company earned $0.88 earnings per share. The firm’s revenue was up 9.0% on a year-over-year basis. equities analysts anticipate that Eli Lilly and Company will post 4.22 EPS for the current fiscal year.
The company also recently declared a quarterly dividend, which will be paid on Friday, December 8th. Investors of record on Wednesday, November 15th will be paid a dividend of $0.52 per share. This represents a $2.08 dividend on an annualized basis and a yield of 2.49%. The ex-dividend date of this dividend is Tuesday, November 14th. Eli Lilly and’s payout ratio is presently 98.58%.
In related news, major shareholder Lilly Endowment Inc sold 180,000 shares of the stock in a transaction that occurred on Thursday, August 31st. The stock was sold at an average price of $81.06, for a total transaction of $14,590,800.00. Following the completion of the transaction, the insider now directly owns 123,865,804 shares of the company’s stock, valued at $10,040,562,072.24. The sale was disclosed in a filing with the SEC, which is available through this link. Over the last three months, insiders have sold 770,000 shares of company stock valued at $64,669,850. 0.20% of the stock is owned by corporate insiders.
Eli Lilly and Company Profile
Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.
Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with Analyst Ratings Network's FREE daily email newsletter.